MR Spectroscopy in Neurodegenerative Disease

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2007 Feb 7

PMID 17279431

Citations 26

Authors

W R Wayne Martin

Affiliations

Soon will be listed here.

Abstract

Unlike traditional, tracer-based methods of molecular imaging, magnetic resonance spectroscopy (MRS) is based on the behavior of specific nuclei within a magnetic field and the general principle that the resonant frequency depends on the nucleus' immediate chemical environment. Most clinical MRS research has concentrated on the metabolites visible with proton spectroscopy and measured in specified tissue volumes in the brain. This methodology has been applied in various neurodegenerative disorders, most frequently utilizing measures of N-acetylaspartate as a neuronal marker. At short echo times, additional compounds can be quantified, including myo-inositol, a putative marker for neuroglia, the excitatory neurotransmitter glutamate and its metabolic counterpart glutamine, and the inhibitory neurotransmitter gamma-aminobutyric acid. 31P-MRS can be used to study high-energy phosphate metabolites, providing an in vivo assessment of tissue bioenergetic status. This review discusses the application of these techniques to patients with neurodegenerative disorders, including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis.

Citing Articles

Interleaved Whole Brain Na-MRI and P-MRSI Acquisitions at 7 Tesla.

Shams Z, Dai J, Gosselink M, Hoogduin H, van der Kemp W, Visser F NMR Biomed. 2025; 38(3):e70012.

PMID: 39956139 PMC: 11830465. DOI: 10.1002/nbm.70012.

Advancements in Brain Research: The In Vivo/In Vitro Electrochemical Detection of Neurochemicals.

Xu X, Zuo Y, Chen S, Hatami A, Gu H Biosensors (Basel). 2024; 14(3).

PMID: 38534232 PMC: 10968235. DOI: 10.3390/bios14030125.

MRI findings in movement disorders and associated sleep disturbances.

Ghaderi S, Karami A, Ghalyanchi-Langeroudi A, Abdi N, Sharif Jalali S, Rezaei M Am J Nucl Med Mol Imaging. 2023; 13(3):77-94.

PMID: 37457325 PMC: 10349287.

Utility of MRI in Quantifying Tissue Injury in Cervical Spondylotic Myelopathy.

Khan A, Haynes G, Mohammadi E, Muhammad F, Hameed S, Smith Z J Clin Med. 2023; 12(9).

PMID: 37176777 PMC: 10179707. DOI: 10.3390/jcm12093337.

Phosphorus metabolism in the brain of cognitively normal midlife individuals at risk for Alzheimer's disease.

Parasoglou P, Osorio R, Khegai O, Kovbasyuk Z, Miller M, Ho A Neuroimage Rep. 2022; 2(4.

PMID: 36532654 PMC: 9757821. DOI: 10.1016/j.ynirp.2022.100121.

References

Oz G, Terpstra M, Tkac I, Aia P, Lowary J, Tuite P . Proton MRS of the unilateral substantia nigra in the human brain at 4 tesla: detection of high GABA concentrations. Magn Reson Med. 2006; 55(2):296-301. DOI: 10.1002/mrm.20761. View

Gruetter R, Adriany G, Choi I, Henry P, Lei H, Oz G . Localized in vivo 13C NMR spectroscopy of the brain. NMR Biomed. 2003; 16(6-7):313-38. PMC: 1513184. DOI: 10.1002/nbm.841. View

Fox P, Raichle M, Mintun M, Dence C . Nonoxidative glucose consumption during focal physiologic neural activity. Science. 1988; 241(4864):462-4. DOI: 10.1126/science.3260686. View

Davie C, Wenning G, Barker G, Tofts P, Kendall B, Quinn N . Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol. 1995; 37(2):204-10. DOI: 10.1002/ana.410370211. View

Marjanska M, Curran G, Wengenack T, Henry P, Bliss R, Poduslo J . Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc Natl Acad Sci U S A. 2005; 102(33):11906-10. PMC: 1188012. DOI: 10.1073/pnas.0505513102. View

Tedeschi G, Litvan I, Bonavita S, Bertolino A, Lundbom N, Patronas N . Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. Brain. 1997; 120 ( Pt 9):1541-52. DOI: 10.1093/brain/120.9.1541. View

Hu M, Taylor-Robinson S, Chaudhuri K, Bell J, Morris R, Clough C . Evidence for cortical dysfunction in clinically non-demented patients with Parkinson's disease: a proton MR spectroscopy study. J Neurol Neurosurg Psychiatry. 1999; 67(1):20-6. PMC: 1736418. DOI: 10.1136/jnnp.67.1.20. View

Ross A, Sachdev P, Wen W, Brodaty H . Longitudinal changes during aging using proton magnetic resonance spectroscopy. J Gerontol A Biol Sci Med Sci. 2006; 61(3):291-8. DOI: 10.1093/gerona/61.3.291. View

Kaufmann P, Pullman S, Shungu D, Chan S, Hays A, Del Bene M . Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology. 2004; 62(10):1753-7. DOI: 10.1212/01.wnl.0000125182.17874.59. View

10.

Hu M, Taylor-Robinson S, Chaudhuri K, Bell J, Labbe C, Cunningham V . Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain. 2000; 123 ( Pt 2):340-52. DOI: 10.1093/brain/123.2.340. View

11.

von Kienlin M, Kunnecke B, Metzger F, Steiner G, Richards J, Ozmen L . Altered metabolic profile in the frontal cortex of PS2APP transgenic mice, monitored throughout their life span. Neurobiol Dis. 2005; 18(1):32-9. DOI: 10.1016/j.nbd.2004.09.005. View

12.

Axelson D, Bakken I, Gribbestad I, Ehrnholm B, Nilsen G, Aasly J . Applications of neural network analyses to in vivo 1H magnetic resonance spectroscopy of Parkinson disease patients. J Magn Reson Imaging. 2002; 16(1):13-20. DOI: 10.1002/jmri.10125. View

13.

Davie C . The role of spectroscopy in parkinsonism. Mov Disord. 1998; 13(1):2-4. DOI: 10.1002/mds.870130104. View

14.

Clark J . N-acetyl aspartate: a marker for neuronal loss or mitochondrial dysfunction. Dev Neurosci. 1998; 20(4-5):271-6. DOI: 10.1159/000017321. View

15.

Ackl N, Ising M, Schreiber Y, Atiya M, Sonntag A, Auer D . Hippocampal metabolic abnormalities in mild cognitive impairment and Alzheimer's disease. Neurosci Lett. 2005; 384(1-2):23-8. DOI: 10.1016/j.neulet.2005.04.035. View

16.

Tofts P, Wray S . A critical assessment of methods of measuring metabolite concentrations by NMR spectroscopy. NMR Biomed. 1988; 1(1):1-10. DOI: 10.1002/nbm.1940010103. View

17.

Matthews P, Francis G, Antel J, Arnold D . Proton magnetic resonance spectroscopy for metabolic characterization of plaques in multiple sclerosis. Neurology. 1991; 41(8):1251-6. DOI: 10.1212/wnl.41.8.1251. View

18.

Allen P, Thompson R, Wilman A . Metabolite-specific NMR spectroscopy in vivo. NMR Biomed. 1998; 10(8):435-44. DOI: 10.1002/(sici)1099-1492(199712)10:8<435::aid-nbm480>3.0.co;2-d. View

19.

Huang W, Alexander G, Chang L, Shetty H, Krasuski J, Rapoport S . Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology. 2001; 57(4):626-32. DOI: 10.1212/wnl.57.4.626. View

20.

Kalra S, Cashman N, Caramanos Z, Genge A, Arnold D . Gabapentin therapy for amyotrophic lateral sclerosis: lack of improvement in neuronal integrity shown by MR spectroscopy. AJNR Am J Neuroradiol. 2003; 24(3):476-80. PMC: 7973590. View